Sugi Predict

Sugi Predict / Compounds / SCHEMBL230519

SCHEMBL230519

SCHEMBL230519

OC(c1ccc(F)cc1)c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.49
▸ CES1 P23141 1/20 0.49
▸ HDAC4 P56524 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ NR3C1 P04150 1/20 0.44
▸ BRD4 O60885 1/20 0.43
▸ IDO1 P14902 1/20 0.42
▸ TDO2 P48775 1/20 0.42
▸ IGFBP3 P17936 1/20 0.41
▸ SLC6A9 P48067 1/20 0.41
▸ SLC6A5 Q9Y345 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL227352 0.91 CES2 (0.55) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL230487 0.89 IDO1 (0.52) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL28788047 0.86 BRD4 (0.49) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL6349980 0.86 CES2 (0.45) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL7082143 0.86 NR3C1 (0.43) CES2CES1NR3C1BRD4
SCHEMBL230516 0.85 CES2 (0.50) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL20862602 0.84 CES2 (0.46) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL6567040 0.83 SLC7A5 (0.47) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL23882733 0.82 CYP11B1 (0.46) CES2CES1HDAC4HDAC7HDAC5
SCHEMBL21831882 0.82 ACHE (0.47) NR3C1BRD4SLC6A9SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 — — CN disclosed
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 — — EP disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-20220324859-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2022-10-13 — — US disclosed
EP-3814348-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 — — EP disclosed
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-23 — — US disclosed
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-23 — — US disclosed
US-20110319444-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2011-12-29 — — US disclosed
WO-2011148888-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST あすか製薬株式会社 (JP) 2011-12-01 — — WO disclosed
US-8039483-B2 Quinuclidine carbonate salts and medicinal composition thereof CHIESI FARMACEUTICI S.P.A. (IT) 2011-10-18 — — US disclosed
CN-102112474-A Quinuclidine carbonate derivatives and medicinal composition thereof CHIESI FARMA SPA 2011-06-29 — — CN disclosed
EP-2313404-A1 QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.p.A. (IT) 2011-04-27 — — EP disclosed
WO-2010015324-A1 QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2010-02-11 — — WO disclosed
US-20100035922-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2010-02-11 — — US disclosed
CN-101437403-A Treatment methods using triaryl methane compounds ICAGEN INC (US) 2009-05-20 — — CN disclosed
CN-1193748-C Gardos channel antagonists ICAGEN INC (US) 2005-03-23 — — CN disclosed
CN-1344158-A Gardos channel antagonists ICAGEN INC (US) 2002-04-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324859-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CES2 4302/4885CES1 2736/4885HDAC4 2391/4885
US-20100035922-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM2, CHRM4 CES2 2730/4885CES1 1576/4885HDAC4 1421/4885
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG CES2 4302/4885CES1 2736/4885HDAC4 2391/4885
US-20110319444-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM2, CHRM4 CES2 2730/4885CES1 1576/4885HDAC4 1421/4885
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG CES2 4302/4885CES1 2736/4885HDAC4 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.